150 related articles for article (PubMed ID: 35752984)
1. A short- and long-term follow-up study of intersphincteric NASHA Dx implants for fecal incontinence.
Ezra E; Danielsson JM; Graf W
Tech Coloproctol; 2022 Oct; 26(10):813-820. PubMed ID: 35752984
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence.
Mellgren A; Matzel KE; Pollack J; Hull T; Bernstein M; Graf W;
Neurogastroenterol Motil; 2014 Aug; 26(8):1087-94. PubMed ID: 24837493
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence.
La Torre F; de la Portilla F
Colorectal Dis; 2013 May; 15(5):569-74. PubMed ID: 23374680
[TBL] [Abstract][Full Text] [Related]
4. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence.
Danielson J; Karlbom U; Sonesson AC; Wester T; Graf W
Dis Colon Rectum; 2009 Jun; 52(6):1101-6. PubMed ID: 19581853
[TBL] [Abstract][Full Text] [Related]
5. Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence.
Franklin H; Barrett AC; Wolf R
Clin Exp Gastroenterol; 2016; 9():41-7. PubMed ID: 27042136
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents.
Danielson J; Karlbom U; Wester T; Graf W
Tech Coloproctol; 2013 Aug; 17(4):389-95. PubMed ID: 23224913
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial.
Graf W; Mellgren A; Matzel KE; Hull T; Johansson C; Bernstein M;
Lancet; 2011 Mar; 377(9770):997-1003. PubMed ID: 21420555
[TBL] [Abstract][Full Text] [Related]
8. Injectable bulking treatment of persistent fecal incontinence in adult patients after anorectal malformations.
Danielson J; Karlbom U; Wester T; Graf W
J Pediatr Surg; 2020 Mar; 55(3):397-402. PubMed ID: 31493885
[TBL] [Abstract][Full Text] [Related]
9. Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence.
Bernstein MA; Purdy CH; Becker A; Magar R
Clin Ther; 2014 Jun; 36(6):890-905.e3. PubMed ID: 24815061
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Noncomparative, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx Gel as a Bulking Agent for the Treatment of Fecal Incontinence.
Dodi G; Jongen J; de la Portilla F; Raval M; Altomare DF; Lehur PA
Gastroenterol Res Pract; 2010; 2010():467136. PubMed ID: 21234379
[TBL] [Abstract][Full Text] [Related]
11. Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence.
Sanchez JE; Brenner DM; Franklin H; Yu J; Barrett AC; Paterson C
Clin Transl Gastroenterol; 2015 Jan; 6(1):e70. PubMed ID: 25588523
[TBL] [Abstract][Full Text] [Related]
12. Perianal injectable bulking agents as treatment for faecal incontinence in adults.
Maeda Y; Laurberg S; Norton C
Cochrane Database Syst Rev; 2013 Feb; (2):CD007959. PubMed ID: 23450581
[TBL] [Abstract][Full Text] [Related]
13. Faecal incontinence: NASHA Dx injection therapy shows long-term efficacy for faecal incontinence.
Greenhill C
Nat Rev Gastroenterol Hepatol; 2014 Jul; 11(7):393. PubMed ID: 24890281
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence.
van Kerrebroeck P; ter Meulen F; Larsson G; Farrelly E; Edwall L; Fianu-Jonasson A
Urology; 2004 Aug; 64(2):276-81. PubMed ID: 15302478
[TBL] [Abstract][Full Text] [Related]
15. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence.
Chapple CR; Haab F; Cervigni M; Dannecker C; Fianu-Jonasson A; Sultan AH
Eur Urol; 2005 Sep; 48(3):488-94. PubMed ID: 15967568
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and functional results of submucosal injection therapy using dextranomer hyaluronic acid for fecal incontinence.
Schwandner O; Brunner M; Dietl O
Surg Innov; 2011 Jun; 18(2):130-5. PubMed ID: 21245071
[TBL] [Abstract][Full Text] [Related]
17. Novel bulking agent for faecal incontinence.
Ratto C; Parello A; Donisi L; Litta F; De Simone V; Spazzafumo L; Giordano P
Br J Surg; 2011 Nov; 98(11):1644-52. PubMed ID: 21928378
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI).
Lone F; Sultan AH; Thakar R
Int Urogynecol J; 2010 Nov; 21(11):1359-64. PubMed ID: 20571764
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and network meta-analysis comparing treatments for faecal incontinence.
Simillis C; Lal N; Pellino G; Baird D; Nikolaou S; Kontovounisios C; Smith JJ; Tekkis PP
Int J Surg; 2019 Jun; 66():37-47. PubMed ID: 31022519
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies.
Al-Bayati I; Saadi M; Elhanafi S; McCallum RW
Am J Med Sci; 2017 Nov; 354(5):476-479. PubMed ID: 29173359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
